Want to see AU:EXL full AI Analyst Report?
Elixinol Wellness (EXL) Share Price & Analysis
EXL Stock Chart & Stats
- Day’s Range
- AUD 0.01 - AUD 0.02
- 52-Week Range
- AUD 0.01 - AUD 0.02
- Previous Close
- AUD 0.02
- Volume
- 100.00K
- Average Volume (3M)
- 5.67M
- Market Cap
- AUD 2.72M
- Enterprise Value
- AUD 5.52M
- Total Cash (Recent Filing)
- AUD 996.00K
- Total Debt (Recent Filing)
- AUD 4.03M
- Price to Earnings (P/E)
- ―
- Beta
- -1.17
- Next Earnings
- Feb 19, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Recovery
Revenue has recovered materially from the 2022–2023 base, indicating that the company retains demand for its branded hemp and CBD wellness products. Although 2025 growth turned negative, the higher revenue platform may support future operating improvement if the business can restore margins and control costs.
Historically Moderate Leverage
Historically moderate debt-to-equity suggests the company had some balance-sheet capacity relative to its equity base before the 2025 deterioration. This provides a stronger starting position than a highly leveraged structure, although preserving that flexibility depends on reducing losses and avoiding further debt increases.
Improving Cash Burn
The direction of cash generation has improved from the much heavier burn recorded in 2020–2022, while 2025 free cash flow was better than in 2024. This suggests some progress in financial control, creating a potential foundation for stronger funding capacity if operations eventually reach positive cash generation.
Bears Say
Persistent Losses
Recurring negative EBIT and net income show that the business has not yet demonstrated durable profitability across the reported period. Continued losses reduce retained capital, limit internally funded investment, and make the company more dependent on operational improvement or external financing to sustain its strategy.
Severe Margin Pressure
The sharp fall in gross profit despite the recovery in revenue indicates substantial pressure on product economics and margin sustainability. If this deterioration persists, higher sales may not translate into improved earnings, weakening the scalability of the branded wellness and CBD business model.
Negative Cash Generation
Consistently negative operating and free cash flow means the company has not shown an ability to fund operations internally. Ongoing cash burn increases reliance on financing while losses persist, reducing strategic flexibility and making balance-sheet resilience more important over the next several quarters.
EXL FAQ
What was Elixinol Wellness’s price range in the past 12 months?
What is Elixinol Wellness’s market cap?
When is Elixinol Wellness’s upcoming earnings report date?
How were Elixinol Wellness’s earnings last quarter?
Is Elixinol Wellness overvalued?
Does Elixinol Wellness pay dividends?
What is Elixinol Wellness’s EPS estimate?
How many shares outstanding does Elixinol Wellness have?
What happened to Elixinol Wellness’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Elixinol Wellness?
What is the TipRanks Smart Score and how is it calculated?
Elixinol Wellness Stock Smart Score
Company Description
Elixinol Wellness
Elixinol Wellness Limited, an entity established in 2017 and headquartered in Sydney, Australia, operates internationally through its subsidiaries. The company is primarily involved in the manufacturing and global distribution of a wide array of hemp-derived products, encompassing nutraceuticals, cosmetics, and various food items. These products are marketed under its distinct brands, Elixinol and Hemp Foods Australia, reaching consumers across the Americas, Europe, and Australia. Its extensive product range features hemp-derived cannabidiol (CBD) items, food products, dietary supplements, and topical skincare solutions. Notably, the company transitioned to its current name in May 2021, having previously been known as Elixinol Global Limited.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Natalie Butler
- Employees
- 15
- Website
- www.elixinolwellness.com
- Address
- 51 - 53 Riversdale Road, Newtown, VIC, 3220, AU
Elixinol Wellness (EXL) Earnings & Revenues
EXL Earnings Call
Earnings Call SentimentPositive
The call communicated meaningful operational progress: a clear shift to higher-margin channels (e-commerce up to 38%), significant cost structure reduction (~30% in Q4 vs prior year), Q4 profitability and positive operating cash flow, strong D2C momentum (Healthy Chef e-commerce +42% YoY) and product innovation poised to capture market trends. However, challenges remain including modest full-year revenue growth (3.6% YoY), a small absolute revenue base (~$15.5M), supermarket channel pressures for niche SKUs, and regulatory uncertainty in the U.S. CBD business. On balance, the operational improvements and trajectory toward sustainable profitability outweigh the outstanding strategic and market risks, but execution and regulatory clarity will be important near-term drivers.
View all AU:EXL earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 4 | 3 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 10 | 0 | 0 |







